Increased proliferative activity and p53 expression in normal glandular breast tissue after radiation therapy

Journal of Pathology

Volumn 185, Issue 1, 1998, Pages 32-37

  Poeze, Martijn ^a   Von Meyenfeldt, Maarten F ^a   Peterse, Johannes L ^b   George, W David ^c   De Jong, Jos M A ^d   Jager, Jos J ^d   Thunnissen, Frederik B J M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c University of 6 Glasgow   (United Kingdom)

^d Radiotherapeutic Institute Limburg   (Netherlands)

Author keywords

Breast; Ki 67; Long term; Morphology; Non malignant tissue; p53; Radiation effects

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CELL DIVISION; COMBINED MODALITY THERAPY; EPITHELIUM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031802367     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199805)185:1<32::AID-PATH43>3.0.CO;2-Q     Document Type: Article

References (43)

1. van Dongen JA, Bartelink H, Bruning PF, Peterse JL. Locoregional treatment of breast carcinoma. Neth J Med 1993; 137: 2358-2363.
2. Mate TP, Carter D, Fisher B, et al. A clinical and histopathological analysis of the results of conservation surgery and radiation therapy in stage 1 and 2 breast carcinoma. Cancer 1986; 58: 1995-2002.
3. Locker AP, Ellis LO, Morgan DA, et al. Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg 1989; 76: 890-894.
4. Fisher B, Bauer M, Margolese R, et al. Five years' results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of early breast cancer. N Engl J Med 1985; 312: 665-673.
5. Fisher B, Redmond C, Poisson R, et al. Eight years' results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822-828.
6. Peterse JL, van Dongen JA, Bartelink H. Recurrence of breast cancer after conserving treatment. Eur J Surg Oncol 1988; 14: 123-126.
7. Lindley R, Bulman A, Parsons P. Histological features predictive of an increased risk of early local recurrence after treatment of breast cancer by local tumour excision and radical radiotherapy. Surgery 1989; 105: 13-20.
8. Fritsche M, Haessler Ch, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307-318.
9. Culotta E, Koshland DE, Jr. p53 sweeps through cancer research. Science 1993; 262: 1958-1961.
10. Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644-1645.
11. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893-899.
12. Horak E, Smith K, Bromley L, et al. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 1991; 6: 2277-2284.
13. Heydermann E, Dagg B. p53 immunostaining in benign breast disease. Lancet 1991; 338: 1532..
14. Sachs RK, Chen AM, Brenner DJ. Review: proximity effects in the production of chromosome aberrations by ionizing radiation. Int J Radiat Biol 1997; 71: 1-19.
15. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996; 40: 197-223.
16. Kotera H, Kusonoki M, Yanagi H, Yamamura T, Utsunomiya J. A possible correlation between p53 overexpression and prognosis after radiotherapy combined surgery for rectal carcinoma. Int J Oncol 1997; 10: 971-975.
17. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-935.
18. Yin Y, Tainsty MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-948.
19. Kastan MB, Zahn Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 5870-597.
20. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by temperature-sensitive mutant of p53. Cell 1990; 62: 671-680.
21. Brugarolas J, Chadndrasekaran C, Gordon JI, Beach D, Jacks T, Hannon G. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552-557.
22. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Der 1991; 5: 151-159.
23. Mercer WE, Shields MT, Anim M, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 1990; 87: 6166-6170.
24. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491-7495.
25. Hall PA, McKee PhH, Menage H du P, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-207.
26. Going JJ, Anderson TJ, Battersby S, Macintyre CCA. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988; 130: 193-204.
27. Diallo I, Lamon A, Shamsaldin A, Grimaud E, de Valthaire F, Chavaudra J. Estimation of the radiation dose delivered to any point outside the target volume per patient treated with external beam radiotherapy. Radiother Oncol 1996; 38: 269-271.
28. McParland BJ. The effect of a dynamic wedge in the medial tangential field upon contralateral breast dose. Int J Radiat Oncol Biol Phys 1990; 19: 1515-1520.
29. Borger J, Kemperman H, Hart A, Peterse JL, van Dongen J, Bartelink H. Risk factors in breast-conserving therapy. J Clin Oncol 1994; 12: 653-660.
30. Macmillan RD, Purushotham AD, Mallon E, Ramsay G, George WD. Breast-conserving surgery and tumour bed positivity in patients with breast cancer. Br J Surg 1994; 81: 56-58.
31. Macmillan RD, Purushotham AD, George WD. Local recurrence after breast-conserving surgery for breast cancer. Br J Surg 1996; 83: 149-155.
32. Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MiB-1 and MiB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-363.
33. Key G, Becker MHG, Baron B, et al. New Ki-67-equivalent murine monoclonal antibodies (MiB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993; 68: 629-635.
34. van Lijnschoten G, Arenas JW, Thunnissen FBJM, Geraedts JPM. A morphometric approach to the relation of karyotype, gestational age and histological features in early spontaneous abortions. Placenta 1994; 15: 189-200.
35. Schnitt SJ, Connolly JL, Harris JR, Cohen RB. Radiation-induced changes in the breast. Hum Pathol 1984; 5: 545-550.
36. Peterse JL, Thunnissen FBJM, van Heerde P. Fine needle aspiration cytology of radiation-induced changes in nonneoplastic breast lesions. Acta Cytol 1989; 33: 176-180.
37. Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK. Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer 1996; 74: 1-5.
38. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991; 6: 1791-1797.
39. Haas-Kogan DA, Yount G, Haas M, et al. p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys 1996; 36: 95-103.
40. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996; 10: 934-947.
41. Chen C-YM, Hall I, Lansing TJ, Gilmer TM, Tlsty TD, Kastan MB. Separate pathways for p53 induction by ionizing radiation and N-(phosphoacetyl)-L-aspartate. Cancer Res 1996; 56: 3659-3662.
42. Swift M, Morrell D, Massey RB, Chase CLC. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-1836.
43. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-776.